Nicoletta Cacciari
10 Papers
89 Citations
Nicoletta Cacciari is an academic researcher. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 6, co-authored 10 publications.
Chat about Author
Papers
FDG-PET/CT in advanced ovarian cancer staging: Value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy
Pierandrea De Iaco,Alessandra Musto,Luca Orazi,Claudio Zamagni,M. Rosati,Vincenzo Allegri,Nicoletta Cacciari,Adil Al-Nahhas,Domenico Rubello,Stefano Venturoli,Stefano Fanti +10 more
TL;DR: PET/CT may prove a useful tool for pre-surgical staging of ovarian cancer with a sensitivity and specificity of 78 and 68%, respectively, however, it may be used in combination with laparoscopy for better results.
111
Early (18)F-2-fluoro-2-deoxy-d-glucose positron emission tomography may identify a subset of patients with estrogen receptor-positive breast cancer who will not respond optimally to preoperative chemotherapy.
Andrea Martoni,Claudio Zamagni,Sara Quercia,M. Rosati,Nicoletta Cacciari,A. Bernardi,Alessandra Musto,Stefano Fanti,Donatella Santini,Mario Taffurelli +9 more
TL;DR: A pathologic complete response (pCR) and minimal residual disease (pMRD) after preoperative chemotherapy for early stage or locally advanced breast cancer correlates with a good prognosis.
66
Oestrogen receptor 1 mRNA is a prognostic factor in ovarian cancer patients treated with neo-adjuvant chemotherapy: determination by array and kinetic PCR in fresh tissue biopsies
Claudio Zamagni,Ralph M. Wirtz,Pierandrea De Iaco,M. Rosati,Elke Veltrup,F. Rosati,Elisa Capizzi,Nicoletta Cacciari,C. Alboni,A. Bernardi,Francesco Massari,Sara Quercia,Antonietta D'Errico Grigioni,Manfred Dietel,Jalid Sehouli,Carsten Denkert,Andrea Martoni +16 more
TL;DR: It is concluded that pretreatment ESR1 mRNA is associated with tumour growth and is a strong prognostic factor in ovarian cancer, independent of the strongest clinical parameters used in clinical routine.
The combination of paclitaxel and carboplatin as first-line chemotherapy in patients with stage III and stage IV ovarian cancer a phase I-II study
TL;DR: The combination of paclitaxel 200 mg/m2 3-hour infusion followed by carboplatin 400 mg/ m2 (30-minute infusion) is a safe and active regimen as first-line chemotherapy for advanced ovarian cancer.
14
Repolarization effects of multiple-cycle chemotherapy and predictors of QTc prolongation: a prospective female cohort study on >2000 ECGs.
Igor Diemberger,Giulia Massaro,Marta Cubelli,Daniela Rubino,Sara Quercia,Cristian Martignani,Matteo Ziacchi,Mauro Biffi,A. Bernardi,Nicoletta Cacciari,Claudio Zamagni,Giuseppe Boriani +11 more
TL;DR: The results confirm the high prevalence of QTc prolongation after chemotherapy and suggest that BC-QTc may help in stratifying arrhythmic risk in real-world clinical practice.
10